Bolt Biotherapeutics (BOLT) vs Medicus Pharma (MDCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bolt Biotherapeutics is the larger company by market cap ($7.9 million vs $138,068), about 57.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLT | MDCX |
|---|---|---|
| Share price | $4.11 | $0.0921 |
| Market cap | $7.92M | $138.07K |
| 1-day change | +13.22% | -9.62% |
| YTD return | — | -93.34% |
| 1-year return | — | -95.86% |
| EPS (TTM) | $-16.51 | $-119.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.20 | $139.00 |
| 52-week low | $3.10 | $0.084 |
| Distance from 52-week high | -42.92% | -99.93% |
| Analyst consensus | none | none |
| Avg. price target upside | +605.60% | +4785.99% |
| Average volume | 26.26K | 92.96K |
| Shares outstanding | 1.93M | 1.50M |
| Employees | 23 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bolt Biotherapeutics is about 57.3 times larger than Medicus Pharma by market value ($7.92M vs $138.07K).
About Bolt Biotherapeutics
BOLT stock →Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
BOLT vs MDCX FAQ
Which is bigger, Bolt Biotherapeutics or Medicus Pharma?
Bolt Biotherapeutics (BOLT) is larger, with a market capitalization of $7.92M compared with $138.07K for Medicus Pharma (MDCX).
Are Bolt Biotherapeutics and Medicus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.